Evaluating antibody functional activity and strain-specificity of vaccine candidates for malaria in pregnancy using in vitro phagocytosis assays

Mirja Hommel1†, Jo-Anne Chan1†, Alexandra J. Umbers1, Christine Langer1, Stephen J. Rogerson2, Joseph D. Smith3 and James G. Beeson1,2,4*

Abstract

Background: Malaria in pregnancy is a major cause of poor maternal and infant health, and is associated with the sequestration of *P. falciparum*-infected erythrocytes (IE) in the placenta. The leading vaccine candidate for pregnancy malaria, VAR2CSA, has been shown to induce antibodies that inhibit IE adhesion to the placental receptor chondroitin sulfate A (CSA), potentially preventing placental infection. However, the ability of vaccination-induced antibodies to promote opsonic phagocytosis is not well defined, but likely to be an important component of protective immunity.

Methods: We investigated the use of an opsonic phagocytosis assay to evaluate antibodies induced by pregnancy malaria vaccine candidate antigens based on VAR2CSA. Opsonic phagocytosis was measured by flow cytometry and visualized by electron microscopy. We measured vaccine-induced antibody reactivity to placental type IEs from different geographical origins, and the functional ability of antibodies raised in immunized rabbits to induce phagocytosis by a human monocyte cell line.

Results: Immunization-induced antibodies showed a mixture of strain-specific and cross-reactive antibody recognition of different placental-binding parasite lines. Antibodies generated against the DBL5 and DBL3 domains of VAR2CSA effectively promoted the opsonic phagocytosis of IEs by human monocytes; however, these functional antibodies were largely allele-specific and not cross-reactive. This has significant implications for the development of vaccines aiming to achieve a broad coverage against diverse parasite strains. Using competition ELISAs, we found that acquired human antibodies among pregnant women targeted both cross-reactive and allele-specific epitopes, consistent with what we observed with vaccine-induced antibodies.

Conclusions: Vaccines based on domains of VAR2CSA induced opsonic phagocytosis of IEs in a strain-specific manner. Assays measuring this phagocytic activity have the potential to aid the development and evaluation of vaccines against malaria in pregnancy.

Keywords: Malaria in pregnancy, Placental malaria, Vaccines, Immunity, Opsonic phagocytosis

* Correspondence: beeson@burnet.edu.au
†Equal contributors
1Burnet Institute, Melbourne, VIC, Australia
2Department of Medicine, Peter Doherty Institute, University of Melbourne, Melbourne, VIC, Australia

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

In malaria endemic areas, pregnant women are at high risk of placental malaria [1]. Despite recent gains in malaria control, approximately 125 million pregnancies remain at risk of malaria and adverse outcomes [2]. Thus, there is an urgent need for the development of effective malaria vaccines. In pregnancy, Plasmodium falciparum-infected erythrocytes (IEs) sequester in the placenta via adhesion to chondroitin sulphate A (CSA) [3]. This interaction is mediated by a specific variant of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family known as VAR2CSA, and possibly other interactions [4]. Although VAR2CSA shows high sequence diversity [5], some antibody epitopes in different domains are partially overlapping between VAR2CSA variants or have limited global antigenic diversity [6–8] and therefore support VAR2 CSA as a potential vaccine candidate. Acquired antibodies directed against VAR2CSA are associated with the inhibition of CSA-binding by IEs [9, 10], reduced placental malaria [11] and improved pregnancy outcomes [12].

To date, the focus of vaccine development in pregnancy malaria has been largely limited to generating antibodies that inhibit adhesion to CSA [13]. However, opsonizing antibodies to the DBL domains of VAR2CSA may also play an important role in protective immunity [14] by acting synergistically with binding-inhibition antibodies, or independently. It is known that cytophilic antibodies to VAR2CSA predominate in pregnancy [14, 15], and these can interact with Fc-receptors to promote the opsonic phagocytosis of IEs [16]. Acquired antibodies to CSA-binding isolates that express VAR2CSA promote opsonic phagocytosis and are associated with better pregnancy outcomes [17, 18]. Furthermore, VAR2CSA-specific monoclonal IgG1 antibodies isolated from malaria-exposed women can opsonize IEs expressing VAR2CSA for phagocytosis by monocytes [19]. Therefore, we investigated the potential use of an established high-throughput, low-cost opsonic phagocytosis assay for evaluating VAR2CSA vaccines.

We used the DBL5 and DBL3 domains of VAR2CSA as our model vaccine antigens as VAR2CSA-specific antibodies acquired from placental infections appear to strongly target these domains [19–21]. Antibodies to both domains have been shown to partially inhibit IE adhesion to CSA [13, 14, 22], thus supporting the idea that these domains might be important targets of protective immunity. Other regions of VAR2CSA are also important targets and vaccine candidates [3], such as the N-terminal region (DBL1-DBL2, and ID1-DBL2X-ID2a), which is under development as a potential vaccine candidate [23–26].

Methods

Study design

To study the properties of vaccine-induced antibodies against pregnancy malaria, we measured the opsonic phagocytosis-inducing potential of antibodies to DBL5 and DBL3 raised through immunization of rabbits, which is a widely used pre-clinical model for malaria vaccine development. We quantified antibody recognition of the IE surface of placental-binding parasites and the level of opsonic phagocytosis activity using a human monocyte cell line, THP-1, which allowed for standardized assays [27]. Immunizations were performed as previously described, under ethics approval [28].

Study participants

Pooled serum samples from malaria-exposed pregnant women residing in Madang, Papua New Guinea and Malawi [6] were used as positive controls. Sera from non-immune adult residents of Melbourne, Australia were used as negative controls.

Materials

Briefly, DBL5 or DBL3 immunization of nine rabbits was performed using one of three recombinant proteins derived from IT4- (equivalent to parasite line CS2), 7G8- or 3D7 DBL5 alleles, as previously described [22]. Parasite isolates expressing VAR2CSA and derived from diverse geographical origins (CS2 (IT isolate, Brazil), HCS3 (Thailand), 3D7-CSA (3D7 reference isolate), XIE-CSA (Papua New Guinea) and 7G8-CSA (Peru)) were maintained and selected for the CSA-binding phenotype as described [6]. The expression of var2csa as the dominant var. gene in these isolates was described previously [6]. Isolate E8B (parental line of CS2 isolate) was used as a non-CSA binding control [7]. Rabbit antibodies were harvested pre-immunization (PI) and final bleed (FB) post-immunization. Analyses of overlap and differences between VAR2CSA sequences from the different isolates, and their relationship to global isolates, has been previously reported [6, 22].

Immunooassays

IgG binding to the IE surface of CSA-binding isolates was measured by flow cytometry using previously established assays [6, 29]. Human immune sera or rabbit anti-DBL5 or anti-DBL3 polyclonal antibodies were tested for their ability to promote the opsonic phagocytosis of IEs using the monocyct cell line THP-1, as described in detail elsewhere [27, 29]. The level of phagocytic activity was measured by flow cytometry and quantified as the proportion of THP1 cells that had phagocytosed IEs (labelled with ethidium bromide); activity was then expressed as a percentage of the activity seen with a positive reference control (rabbit anti-human erythrocyte antibody or pooled...
serum from malaria-exposed pregnant women) [27, 29]. A pool of serum from residents of Melbourne, Australia, was used as a negative control in all assays. Phagocytosis of IEs by THP-1 monocytes was also visualized by scanning and transmission electron microscopy using standard techniques [29, 30]. *Plasmodium falciparum* was cultured in vitro in medium supplemented with 10% pooled human serum [6]. Statistics were performed using GraphPad Prism Software version 6.0. Competition ELISAs were used to evaluate cross-reactive and allele-specific antibodies to DBL5; to this end, serum samples were incubated with titrated amounts (10, 5, 0.5 and 0.005 μg/ml) of 7G8- or 3D7-derived DBL5 for 1 h at room temperature. Pre-incubation with PBS was used as control. All sera were then tested for reactivity to DBL5 in ELISA at a final concentration of 1:250 and 50 μl were used per well. A selection of serum samples from malaria-exposed pregnant women resident in Malawi were used in these assays.

**Results**

**Antibody levels and recognition of IEs**

Previous studies demonstrated that antibodies to DBL5 raised in rabbits reacted with recombinant proteins by ELISA [22]. IgG from rabbits immunized with different DBL5 alleles (IT4, 7G8 and 3D7) showed varied reactivity to native VAR2CSA expressed on the surface of IEs of different CSA-binding parasite lines when measured by flow cytometry (Fig. 1a), as reported previously [22]. IgG-binding showed a significant amount of strain-specificity and only partial cross-reactivity between different CSA-binding isolates that express VAR2CSA, despite there being substantial sequence identity between the different DBL5 alleles [21]. Total IgG binding to the surface of CS2 IEs was highest in sera from animals immunized with the DBL5 IT4 allele. IgG binding to 3D7-CSA IEs was highest in rabbits immunized with the DBL5 3D7 allele, but overall antibodies raised against the 3D7 allele showed broader reactivity across isolates. The DBL5 domain had been previously identified as an important target of naturally acquired antibodies in pregnant women [21].

**Vaccine antibodies promote opsonic phagocytosis of IEs expressing VAR2CSA**

We tested rabbit antibodies for their ability to promote the opsonic phagocytosis of CS2 and E8B IEs (non-CSA binding line, same genotype as CS2). Antibodies generated by immunization induced significantly higher levels of opsonic phagocytosis of CS2 IEs compared to pre-immunization sera (Fig. 1b; \( t_{(2)} = 6.3, P = 0.024 \)). However, there was very little opsonic phagocytosis with IEs of the E8B line, which does not express VAR2CSA or bind to CSA (Fig. 1b; \( t_{(2)} = 0.3, P = 0.74 \)) [1]. This confirms that the opsonic phagocytosis mediated by anti-DBL5 antibodies is largely specific, identifying the potential use of this assay for VAR2CSA vaccine evaluation. The initial attachment and engulfment of CS2 IEs by THP-1 monocytes was visualized by scanning (Fig. 1c) and transmission (Fig. 1d) electron microscopy. Phagocytosis of IEs was observed with IEs opsonized with antibodies from malaria-exposed pregnant women from PNG or polyclonal rabbit anti-DBL5 antibodies. These images show, for the first time, processes from THP-1 cells attaching to IEs to initiate engulfment and further support data from flow cytometric analyses of phagocytosis.

**Opsonic phagocytosis activity of vaccine anti-VAR2CSA DBL5 antibodies is strain-specific**

To investigate the strain-specificity or cross-reactivity of vaccine-induced opsonizing antibodies to placental-binding parasite isolates, we measured levels of phagocytosis induced by opsonization with the genetically distinct isolates 7G8-CSA (Fig. 1e) and HCS3 (Fig. 1f). Antibodies to IT4 DBL5 did not effectively promote substantial opsonic phagocytosis of either 7G8-CSA or HCS3 IEs. In contrast, sera from malaria-exposed Malawian pregnant women, used as a positive control, promoted high levels of phagocytosis with both parasite lines. This suggests that antibodies raised against the DBL5-IT4 variant do not cross-react well enough to promote sufficient opsonic phagocytosis in heterologous CSA-binding parasite isolates.

We extended these studies by testing antibodies raised against the DBL3 domain (IT4 allele). Antibodies to DBL3 also effectively promoted opsonic phagocytosis of the homologous isolate, CS2-IEs (Fig. 1g). However, as seen with DBL5 antibodies, there was little phagocytosis of a heterologous isolate, HCS3, indicating strain-specificity of these functional antibodies (Fig. 1h). These findings have significant implications for generating broadly reactive antibodies by vaccines based on VAR2CSA.

**Naturally acquired antibodies in pregnant women target variant-specific and cross-reactive antibodies on DBL5**

To further understand the allele-specific activity of antibodies to VAR2CSA domains, we evaluated antibodies from a selection (\( n = 10 \)) of malaria-exposed pregnant women for cross-reactive and allele-specific antibodies to DBL5 using competition ELISAs. Samples that showed significant reactivity to the two alleles of DBL5 that were included in these assays. We evaluated the ability of the DBL5-3D7 to inhibit IgG binding to DBL5-7G8, and vice versa (Fig. 2). Overall, we found evidence of a mixture of cross-reactive and allele-specific antibodies, with substantial variation between individuals in the relative levels of cross-reactive or allele-specific antibodies. These findings are consistent with our observations that vaccine-induced
antibodies comprise allele-specific and cross-reactive antibodies and that there are significant antigenic differences between DBL5 alleles. Because human antibodies are comprised of a mixture of antibodies to different VAR2CSA domains and alleles acquired through natural exposure, it is not possible to test these for allele-specificity in functional
assays using intact IEs. Future studies using human monoclonal antibodies and/or domain-specific affinity-purified antibodies may be needed to investigate this further.

Discussion

We conducted an exploratory study to evaluate the potential value of a high-throughput opsonic phagocytosis assay to measure functional immunity generated by candidate VAR2CSA vaccines. We used antibodies generated against the DBL5 domain, which is an important target of human antibodies, contains cross-reactive epitopes and antibodies against DBL5 have been shown to inhibit adhesion [13, 21, 22]. Studies were extended to antibodies against the DBL3 domain, which is also a target of acquired immunity [19] and antibodies to this domain can inhibit adhesion [13, 21]. Furthermore, prior studies have suggested that global diversity of DBL3 domains may be limited [6], which would be favorable for vaccine development. Our findings demonstrate that immunization with these recombinant VAR2CSA domains induced antibodies capable of opsonizing IEs for phagocytic clearance by monocytes, thus further supporting these domains for inclusion in a VAR2CSA-based vaccine. We also visualized the initial attachment and engulfment of IEs, opsonized by vaccine-induced antibodies using electron microscopy. Importantly, the functional activity of these vaccine-induced antibodies appears to have substantial strain-specificity, despite some level of cross-reactivity to native VAR2CSA on the surface of intact IEs being detected when quantified by flow cytometry. Our findings suggest that

![Image](image.png)

**Fig. 2** Naturally acquired antibody responses to DBL5 domain of VAR2CSA. A selection of sera from malaria-exposed Malawian women was tested for allele-specific or cross-reactive IgG binding to DBL5 in competition ELISA. Panels a-f show examples with cross-reactivity, allele-specificity, or a mixed pattern. Figures show the percent IgG reactivity with increasing concentration of competing DBL5 allele added. Panels a, c, e show results where plates were coated with 7G8 allele and either 7G8 or 3D7 alleles were used as the competitors. Panels b, d, and f show results using the 3D7 allele as the coating antigens. Median values (with IQR) of percentage allele specificity for all individuals (n = 10) tested are also shown in g and h. **P = 0.0046**
vaccination with a single VAR2CSA allele is unlikely to generate broadly reactive opsonizing antibodies that cover the global diversity present in VAR2CSA, which is consistent with previous findings of strain-specificity of human acquired antibodies [7]. Further studies are required to identify vaccine constructs, allele combinations, or approaches that will induce strain-transcendent activity. For example, an antigen derived from the N-terminal region (ID1-DBL2x) has generated cross-reactive antibodies that inhibit adhesion, and looks promising as a vaccine candidate [26].

Malaria-exposed multigravid women naturally acquire antibodies that promote the phagocytosis of CSA-binding IEs [31]. This immune response has been proposed to contribute to protection against maternal anemia [32] and low birth weight [18]. The capacity of these naturally acquired antibodies to promote opsonic phagocytosis of IEs has been validated using human immune sera [18, 31, 32]. Recent studies have also suggested that VAR2CSA is a major target of naturally-acquired human antibodies that promote the phagocytosis of CSA-binding IEs [14]. Here, we demonstrate a high throughput flow cytometry-based phagocytosis assay as an appropriate tool to evaluate antibody responses generated by candidate VAR2CSA vaccines and complement the more established adhesion-inhibition assay. Using this approach, we showed that a potential malaria vaccine candidate is able to elicit functional antibodies that promote the opsonic phagocytosis of placental-binding IEs. Furthermore, studies with P. falciparum isolates engineered to have reduced or absent PfEMP1 expression suggested that PfEMP1 is the dominant target of acquired antibodies to the IE surface among children, non-pregnant adults, and pregnant women, including antibodies that promote opsonic phagocytosis [29, 33].

We observed variable antibody recognition of different CSA-binding IE isolates by antibodies against different DBL5 alleles, suggesting a degree of cross-reactivity, but some strain-specificity, likely due to sequence diversity as noted previously [1, 7, 22, 28]. Despite the DBL5-IT4 immune sera showing moderate recognition of 7G8-CSA and HCS3 isolates by flow cytometry (in addition to high reactivity to CS2 IEs), this did not translate to functional antibody activity. Some recent data suggest that anti-DLB5 adhesion-blocking antibodies may be more strain-transcendent [34]. Our findings using competition ELISA with samples from malaria-exposed pregnant women also support the conclusion that antibodies to DBL5 are comprised of both strain-specific and cross-reactive antibodies. We chose the DBL5 domain as a model VAR2CSA vaccine candidate, and extended our findings to another important domain, DBL3. However, other domains may also induce opsonic phagocytosis [19] and a further detailed analysis of the cross-reactivity or strain-specificity of leading VAR2CSA vaccine candidates should be assessed. As this study aimed to establish a proof-of-principle, its scope was exploratory in nature and we did not perform an exhaustive analysis of all proposed vaccine constructs.

Conclusions
Effective vaccine design aims for the generation of broadly cross-reactive antibodies to various isolates, and possibly antibodies with multiple functional activities. Vaccine development also requires the establishment of laboratory assays that can predict functional immunity. Findings presented here further support the use of phagocytosis assays as a complementary approach to assessing current and future vaccine candidates aimed at preventing malaria in pregnancy.

Additional file

**Additional file 1: Table S1.** The raw data supporting Fig. 1. (XLSX 37 kb)

**Abbreviations**

CSA: Chondroitin sulfate A; DBL5: Duffy binding-like domain 5; ELISA: Enzyme-linked immune-sorbent assay; IE: Plasmodium falciparum-infected erythrocytes; PfEMP1: Plasmodium falciparum erythrocyte membrane protein 1; PNG: Papua New Guinea; VAR2CSA: Variant surface antigen 2 against chondroitin sulfate A

**Acknowledgements**

We thank Wina Hasang for technical advice, the participants in the studies of malaria in pregnancy, and the Australian Red Cross Blood Service for cells and serum for parasite culture.

**Funding**

We acknowledge the funding provided by the National Health and Medical Research Council of Australia (Project Grant, Senior Research Fellowship to JGB, Project Grant to SJR, Independent Research Institutes Infrastructure Support), and Operational Infrastructure Support from the State Government of Victoria, Australia. The funding bodies did not have any role in the design or preparation of this manuscript.

**Availability of data and materials**

The data supporting the conclusions of this article are included within the article. The raw data supporting Fig. 1 are included as an Additional file 1. We do not have the human ethics approval to publish the raw data supporting Fig. 2.

**Authors’ contributions**

MH designed and carried out experiments, performed analysis and contributed to writing and reviewing the manuscript. JAC performed experiments, contributed to imaging studies and drafting and reviewing the manuscript. AU compiled and analyzed the data and drafted the manuscript with JGB. CL performed imaging studies and data interpretation. JDS generated vaccine antibodies and contributed to study design and manuscript preparation. SJR provided human samples and contributed to manuscript preparation. JGB conceived and designed the study and contributed to data analysis and drafting the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Ethical approval was provided by the Human Research and Ethics Committees of Alfred Health and Melbourne Health, Australia, and from the College of Medicine, University of Malawi, and the Medical Research Advisory Committee, PNG. All study participants gave written informed consent.

**Consent for publication**

Not applicable.
Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Burnet Institute, Melbourne, VIC, Australia. 2Department of Medicine, Peter Doherty Institute, University of Melbourne, Melbourne, VIC, Australia. 3Center for Infectious Diseases Research, Seattle, WA, USA. 4Department of Microbiology and Central Clinical School, Monash University, Clayton, VIC, Australia.

Received: 11 July 2017 Accepted: 16 January 2018

Published online: 29 January 2018

References
1. Beeson JG, Brown GV. Plasmodium falciparum-infected erythrocytes demonstrate dual specificity for adhesion to hyaluronic acid and chondroitin sulphate a and have distinct adhesive properties. J Infect Dis. 2004;189:169–79.
2. Dellocour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med. 2010;7:e1000221.
3. Fried M, Duffy PE. Designing a VAR2CSA-based vaccine to prevent placental malaria. Vaccine. 2015;33:7483–8.
4. Salanti A, Staalose T, Lavstsen T, Jensen AT, Sova MPK, Amot DE, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol. 2003;49:179–91.
5. Trimnell AR, Kraemer SM, Mukherjee S, Phippard DJ, James JH, Flomo E, et al. Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. Mol Biochem Parasitol. 2006;148:169–80.
6. Hommel M, Elliott SR, Soma V, Kelly G, Fowkes FJ, Chenlon JM, et al. Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women. Infect Immun. 2010;78:1963–78.
7. Beeson JG, Mann EJ, Byrne TJ, Caragounis A, Elliott SR, Brown GV, et al. Antigenic differences and conservation among placental Plasmodium falciparum-infected erythrocytes and acquisition of variant-specific and cross-reactive antibodies. J Infect Dis. 2006;193:721–30.
8. Bockhorst J, Lu F, Janes JH, Keebler J, Gamain B, Awadalla P, et al. Structural polymorphism and diversifying selection on the pregnancy malaria vaccine candidate VAR2CSA. Mol Biochem Parasitol. 2007;155:103–12.
9. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies to block malaria. Nature. 1998;395:851–2.
10. Beeson JG, Mann EJ, Elliott SR, Lema VM, Tadesse E, Molyneux ME, et al. Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. J Infect Dis. 2004;189:540–51.
11. Stålsöe T, Megneko R, Fievé N, Ricke CH, Zornig HD, Leke R, et al. Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. J Infect Dis. 2001;184:128–135.
12. Stålsöe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet. 2004;363:283–9.
13. Fried M, Avril M, Chatunvedi R, Fernandez P, Lograsso J, Narum D, et al. Multilaboratory approach to preclimbing evaluation of vaccine immunogens for placental malaria. Infect Immun. 2013;81:487–95.
14. Lambert LH, Bullock JL, Cook ST, Miura K, Garboci D, Díakite M, et al. Antigen reversal identifies targets of opsonizing IgGs against pregnancy-associated malaria. Infect Immun. 2014;82:4842–53.
15. Elliott SR, Brennan AK, Beeson JG, Tadesse E, Molyneux ME, Brown GV, et al. Placental malaria induces variant-specific antibodies of the cytophilic subtypes immunoglobulin G1 (IgG1) and IgG3 that correlate with adhesion inhibitory activity. Infect Immun. 2005;73:5903–7.
16. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.
17. Feng G, Aitken E, Yosaatmadja F, Kalfani L, Meshnick S, Jaworowski A, et al. Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anaemia in pregnancy. J Infect Dis. 2009;200:299–306.
18. Ataide R, Mwapasa V, Molyneux ME, Meshnick SR, Rogerson SJ. Antibodies that induce phagocytosis of malaria infected erythrocytes: effect of HIV infection and correlation with clinical outcomes. PLoS One. 2011;6:e22491.
19. Barford L, Dobrović T, Magistrado P, Khunaae P, Wiwami F, Bruun J, et al. Chondroitin sulphate A-adhering Plasmodium falciparum-infected erythrocytes express functionally important antibody epitopes shared by multiple variants. J Immunol. 2010;185:7553–61.
20. Salanti A, Dahlbäck M, Turner L, Nielsen MA, Barford L, Magistrado P, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med. 2004;200:1197–203.
21. Avril M, Cartwright MM, Hathaway MJ, Smith JD. Induction of strain-transcendental antibodies to placental-type isolates with VAR2CSA DBL3 or DBL5 recombinant proteins. Malar J. 2011;10:36.
22. Avril M, Cartwright MM, Hathaway MJ, Hommel M, Elliott SR, Williamson K, et al. Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes. Infect Immun. 2010;78:2248–6.
23. Chêne A, Houard S, Nielsen MA, Houdt S, D’ Alessio F, Srimal SB, et al. Clinical development of placental malaria vaccines and immunooasays harmonization: a workshop report. Malar J. 2016;15:476.
24. Rajvani J, Klinger CM, Arango E, Arroyo MI, Sabbagh A, Maestra A, et al. Genetic analysis of ID1-DBL2X predicts its validity as a vaccine candidate in Colombia and supports at least two independently introduced Plasmodium falciparum populations in the region. Infect Genet Evol. 2017;55:175–85.
25. Doritchamy JA, Herrera R, Ateit J, Morrison N, Nguyen V, Reiter K, et al. VAR2CSA domain-specific analysis of naturally acquired functional antibodies to Plasmodium falciparum placental malaria. J Infect Dis. 2016;214:577–86.
26. Bordbar B, Tulpau-Iamn N, Bigyi P, Doritchamy J, Scherman D, Deloron P. Identification of ID1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies. Vaccine. 2012;30:1433–8.
27. Ataide R, Hasang W, Wilson DW, Beeson JG, Mwapasa V, Molyneux ME, et al. Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria. PLoS One. 2011;6:e1807.
28. Avril M, Kulausska BR, Goze SO, Rowe C, Dahlbäck M, Duffy PE, et al. Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA. Infect Immun. 2008;76:1791–800.
29. Chan J-A, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJ, et al. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J Clin Invest. 2012;122:3027–38.
30. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, et al. Osponic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med. 2014;12:108.
31. Keen J, Serghides L, Ayi K, Patel SN, Ayisi J, van Eijk A, et al. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Med. 2007;4:e181.
32. Jaworowski A, Fernandes LA, Yosaatmadja F, Feng G, Mwapasa V, Molyneux ME, et al. Relationship between human immunodeficiency virus type 1 coinfection, anemia, and levels and function of antibodies to variant surface antigens in pregnancy-associated malaria. Clin Vaccine Immunol. 2009;16:312–9.
33. Chan J-A, Howell KB, Diering L, Ataide R, Mackintosh CL, Song J, et al. A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies. Cell Mol Life Sci. 2016;73:4141–58.
34. Fernandez P, Petres S, Meceth S, Gyenis J, Scheff A. Strain-transcendent immune response to recombinant VAR2CSA DBL-e domain block P falciparum adhesion to placenta-derived BeWo cells under flow conditions. PLoS One. 2010;5:e12558.